Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
Table 3
On-Treatment Adverse Events Reported in at Least 10% of Mipomersen Patients.
Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click here.
On-Treatment Adverse Events Reported in at Least 10% of Mipomersen Patients.